Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
01 oct. 2024 07h00 HE
|
Kailera Therapeutics, Inc.
Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.
BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes
13 avr. 2023 14h03 HE
|
BioAegis Therapeutics
Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...
$2.7 Billion Worldwide Pet Diabetes Care Industry to 2027 - Players Include ACON Laboratories, Allison Medical, i-SENS and Trividia Health
15 déc. 2022 04h50 HE
|
Research and Markets
Dublin, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The "Pet Diabetes Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Yale School of Medicine to Present Data on Reversal of Fatty Liver and Plasma Triglycerides in NHPs
04 févr. 2020 08h30 HE
|
Crown Bioscience
SAN DIEGO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the presentation of new NAFLD/NASH data with Yale School of Medicine. The presentation encompasses preclinical...
Crown Bioscience Inc. and Charles River Laboratories Enter Agreement to Expand Access to ZDSD Rat Model
12 mars 2019 08h30 HE
|
Crown Bioscience
SAN DIEGO, Calif. and WILMINGTON, Mass., March 12, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance...
Crown Bioscience Expands Cardiovascular & Metabolic Disease Research Capability
08 nov. 2018 08h00 HE
|
Crown Bioscience
The Company Offers New Non-GLP Services & Translational Rodent Models at its expanded site in Louisiana SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug...
Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring
23 nov. 2017 08h00 HE
|
Crown Bioscience
SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development...
CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research Programs
21 nov. 2017 08h00 HE
|
Crown Bioscience
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development...
CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes
10 oct. 2017 09h31 HE
|
Crown Bioscience
SANTA CLARA, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development...
Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise in Global Strategy and Commercial Leadership to the Role
27 sept. 2017 08h00 HE
|
Crown Bioscience
SANTA CLARA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development...